The largest drugmaker within Britain, GlaxoSmithKline, has been hit with the latest in a serious of multinational controversies regarding so-called pay-for-delay deals, used when drugmakers pay the producers of generic drugs to keep their products, often less expensive than brand-names, off the shelves. GSK had reportedly defended its business practices and denied any wrongdoing, but the Office of Fair Trading has accused the company of abusing its market dominance by paying the makers of the generic form of antidepressant Seroxat to delay the sale of their version of the drug. According to the OFT, GSK is accused of colluding with Alpharma, Gerics and Norton Healthcare over the supply of the drug about 10 years ago. The supply agreements were reportedly terminated in 2004. Similar investigations have been initiated within the US and Europe.
Full Content: Euronews
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI